High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2).

Authors :: Mauro FR
Molica S
Soddu S
Ilariucci F
Coscia M
Zaja F
Angelucci E
Re F
Liberati AM
Tedeschi A
Reda G
Pietrasanta D
Gozzetti A
Battistini R
Del Poeta G
Musolino C
Nanni M
Piciocchi A
Vignetti M
Neri A
Albano F
Cuneo A
Del Giudice I
Della Starza I
De Propris MS
Raponi S
Guarini AR
Foà R
Source :: Haematologica [Haematologica] 2020 Nov 01; Vol. 105 (11), pp. 2671-2674. Date of Electronic Publication: 2020 Nov 01.
Publication Year :: 2020

Subjects :: Antibodies, Monoclonal, Humanized therapeutic use
Antineoplastic Combined Chemotherapy Protocols adverse effects
Cyclophosphamide therapeutic use
Humans
Rituximab therapeutic use
Treatment Outcome
Vidarabine analogs & derivatives
Vidarabine therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell genetics

Full Text Access

Tools